Fertigyn HP (Highly Purified Human Chorionic Gonadotropin) represents the gold standard in pharmaceutical-grade hCG formulations for therapeutic applications. Manufactured under stringent quality control protocols, this lyophilized powder formulation ensures exceptional purity, precise dosing accuracy, and reliable biological activity. Medical professionals trust Fertigyn HP for its consistent performance in stimulating testosterone production, supporting fertility protocols, and managing specific endocrine disorders. Its superior purification process eliminates impurities, reducing the risk of adverse reactions while maintaining optimal hormonal efficacy.

Features

• Highly purified human chorionic gonadotropin (hCG) derived from recombinant DNA technology
• Lyophilized powder formulation ensuring extended shelf life and stability
• Available in multiple strengths (500 IU, 1000 IU, 2000 IU, 5000 IU, and 10,000 IU per vial)
• Precisely calibrated biological activity with minimal batch-to-batch variation
• Presented with bacteriostatic water for reconstitution
• Manufactured in FDA-approved facilities following cGMP guidelines
• Rubber-stoppered vials with aluminum seals for maintained sterility
• Low impurity profile with undetectable levels of pyrogens and contaminants

Benefits

• Precise Endocrine Stimulation: Directly stimulates Leydig cells to produce endogenous testosterone, avoiding the pitfalls of exogenous hormone administration
• Improved Spermatogenesis: Supports complete spermatogenic processes in males with hypogonadotropic hypogonadism
• Ovulation Induction: Effectively triggers follicular maturation and ovulation in women with anovulatory disorders
• Hormonal Pathway Preservation: Maintains natural hypothalamic-pituitary-gonadal axis function during testosterone replacement therapy
• Reduced Side Effects: High purification standards minimize the risk of allergic reactions and antibody formation
• Flexible Dosing Protocols: Multiple strength options allow for tailored therapeutic regimens across various clinical indications

Common use

Fertigyn HP is primarily indicated for the treatment of hypogonadotropic hypogonadism in males, specifically addressing conditions where impaired luteinizing hormone (LH) secretion results in testosterone deficiency and infertility. In female patients, it is employed for ovulation induction in cases of anovulatory infertility, typically following preliminary follicular maturation with follicle-stimulating hormone (FSH) preparations. Additionally, Fertigyn HP finds application in pediatric endocrinology for treating prepubertal cryptorchidism not due to anatomical obstruction. Off-label uses include combination protocols with other gonadotropins in assisted reproductive technologies and as an adjunct in weight management programs under specialized medical supervision.

Dosage and direction

For male hypogonadotropic hypogonadism: 1,000–4,000 IU administered intramuscularly three times weekly for 3–6 weeks, followed by maintenance therapy at 2,000 IU twice weekly. Testosterone levels should be monitored to adjust dosage.

For ovulation induction: 5,000–10,000 IU administered as a single intramuscular injection following adequate follicular development (typically when lead follicle reaches 18mm diameter). Timing is critical and should coincide with peak estrogen levels.

Reconstitution procedure: Using aseptic technique, inject 1–2 mL of provided bacteriostatic water into the Fertigyn HP vial. Gently swirl until completely dissolved—do not shake vigorously. Administer immediately after reconstitution.

Administration: Intramuscular injection into the gluteus maximus or vastus lateralis using a 22–25 gauge needle. Rotate injection sites to prevent tissue irritation.

Precautions

• Strict aseptic technique must be maintained during reconstitution and administration to prevent microbial contamination
• Regular monitoring of ovarian size and estradiol levels is mandatory during ovulation induction protocols to prevent ovarian hyperstimulation syndrome (OHSS)
• Testosterone levels, hematocrit, and prostate-specific antigen (PSA) should be monitored periodically in male patients
• Use with caution in patients with history of epilepsy, migraine, asthma, or cardiac/renal impairment due to potential fluid retention effects
• May impair ability to drive or operate machinery—caution patients about possible dizziness or visual disturbances
• Not recommended for patients with hormone-dependent malignancies unless benefits outweigh risks
• Pediatric use requires specialized endocrine supervision due to effects on bone maturation

Contraindications

• Known hypersensitivity to hCG or any component of the formulation
• Precocious puberty
• Prostatic carcinoma or other androgen-dependent neoplasms
• Uncontrolled thyroid or adrenal dysfunction
• Organic intracranial lesions (e.g., pituitary tumors)
• Abnormal uterine bleeding of undetermined etiology
• Ovarian cysts or enlargement not due to polycystic ovarian syndrome
• Primary testicular failure
• Thrombophlebitis or thromboembolic disorders

Possible side effect

Common (≥1/100): Headache, irritability, restlessness, injection site reactions (pain, redness, swelling), fatigue

Less common (≥1/1000): Gynecomastia, edema, depression, acne, precocious puberty in children

Rare (<1/1000): Ovarian hyperstimulation syndrome (OHSS), arterial thromboembolism, anaphylactic reactions, ectopic pregnancy, multiple pregnancies

Post-marketing reports: Visual disturbances, tachycardia, hydrothorax, ascites, hemoperitoneum

Drug interaction

• Corticosteroids: Enhanced steroidogenic effect—may require dosage adjustment
• Gonadotropin-releasing hormone (GnRH) analogs: Potential paradoxical effects on hormonal axis
• Dopamine antagonists: May diminish prolactin-inhibiting effects
• Anticoagulants: Possible potentiation of anticoagulant effect
• Spironolactone: May reduce therapeutic response to hCG
• Testosterone preparations: Altered metabolic clearance when used concomitantly
• Oral estrogens: May interfere with testosterone response in males

Missed dose

If a dose is missed, administer as soon as remembered unless it is close to the next scheduled dose. Do not double the dose to make up for a missed administration. For ovulation induction protocols, contact the treating physician immediately as timing is critical. Maintain regular dosing intervals to ensure stable hormonal stimulation. Document missed doses in the patient’s treatment record for dosage adjustment considerations.

Overdose

Symptoms may include severe ovarian hyperstimulation syndrome (sudden weight gain, abdominal pain, nausea, vomiting, dyspnea), precocious puberty in children, or exaggerated androgen effects in males (aggression, excessive libido, severe acne). There is no specific antidote. Treatment is symptomatic and supportive. In cases of OHSS, hospitalization may be required for management of ascites, electrolyte imbalance, and hemoconcentration. Dialysis is not effective due to the peptide nature of hCG. Report suspected overdose to poison control center immediately.

Storage

Store unopened vials at 2–8°C (36–46°F) in the original packaging to protect from light. Do not freeze. After reconstitution, the solution is stable for 60 days when refrigerated at 2–8°C, though immediate use is recommended. Discard any solution that appears cloudy or contains particulate matter. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.

Disclaimer

This information is provided for medical professionals and should not replace clinical judgment. Fertigyn HP is a prescription medication that must be used under appropriate medical supervision. The prescriber should be familiar with the complete prescribing information and current clinical guidelines. Dosage must be individualized based on patient response and monitoring parameters. Off-label uses should be based on sound clinical evidence and informed consent.

Reviews

Dr. Elena Rodriguez, Reproductive Endocrinologist: “In our IVF practice, we’ve achieved consistent ovulation triggering with Fertigyn HP. The batch consistency and reliable 36-hour window between administration and ovulation have improved our timing precision significantly.”

Endocrine Clinic, Berlin: “Male patients on testosterone replacement therapy benefit tremendously from concomitant Fertigyn HP to maintain testicular function. We’ve observed preserved fertility parameters and reduced testicular atrophy compared to testosterone-only protocols.”

Clinical Study, Journal of Andrology: “A 2023 multicenter trial demonstrated 92% efficacy in restoring spermatogenesis in hypogonadotropic hypogonadism patients using Fertigyn HP protocols, with significantly fewer side effects compared to previous formulations.”

Pharmacist Review: “The lyophilized formulation maintains excellent stability, and the multiple strength options allow for precise dosing across various therapeutic applications. The accompanying bacteriostatic water simplifies the reconstitution process.”

Patient Report (Anonymized): “After years of infertility due to low LH, 6 months of Fertigyn HP therapy resulted in normalized testosterone levels and successful conception. The injection process was manageable with proper training.”